Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
225Ac-Dotadipep
- Development stage
- Preclinical
- Lead developer
- FutureChem
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
225Ac-Dotadipep is a PSMA-targeted alpha-particle radioligand therapy (TAT) currently in preclinical development by FutureChem for the treatment of prostate cancer. The drug consists of a ligand, Dotadipep, which specifically binds to the prostate-specific membrane antigen (PSMA) overexpressed on prostate cancer cells, conjugated to the alpha-emitting radioisotope actinium-225 (225Ac). Upon binding and internalization, the high-energy alpha particles emitted by 225Ac induce lethal double-strand DNA breaks within the cancer cells, offering a potent therapeutic effect even in cases resistant to beta-emitting radiopharmaceuticals like 177Lu-PSMA-617. The use of alpha emitters is intended to provide higher linear energy transfer (LET) and a shorter range in tissue, potentially increasing efficacy while reducing off-target toxicity.
- Other names
- Actinium-225 DotadipepActinium225 DotadipepActinium 225 Dotadipep
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 225Ac-Dotadipep.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 225Ac-Dotadipep.